Essilor® Stellest® Lenses
Don't just correct myopia – slow the progression
References:
- Essilor International, data on file (2025).
- Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
- Essilor International, data on file (2025).
- Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
- Essilor International, data on file (2025).
- Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
- Essilor International, data on file (2025).
- The U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the Essilor® Stellest® spectacle lens in April 2021.
- Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
- Essilor International, data on file (2025).
